Proteomics International Laboratories' (ASX:PIQ) March quarter update contained no major surprises as the company largely reiterated its guided timelines, Euroz Hartleys said in a Thursday note.
The research firm noted that the recent placement and share purchase plan should provide the company with adequate cash for 12 months, with about AU$8.6 million in pro forma cash, assuming the plan is successful.
The research firm said their investment case is based on the company securing a US licensing partner for its product PromarkerD and for its broader test pipeline, over the medium term.
Euroz Hartleys changed Proteomics International Laboratories' rating to speculative buy from hold and cut its price target to AU$0.50 from AU$0.72.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。